pixatrone
Roche’s Columvi improves survival in large B-cell lymphoma
Approximately 160,000 people are diagnosed with this aggressive form of cancer each year
Gilead’s Yescarta shows benefits for patients with large B-cell lymphoma
This is the most common type of non-Hodgkin lymphoma worldwide
Roche’s Lunsumio receives positive CHMP opinion for follicular lymphoma
The recommendation for the subcutaneous formulation follows encouraging trial data
Roche’s fixed-duration lymphoma treatment approved by European Commission
Approximately 36,000 people are diagnosed with DLBCL each year in Europe
ADC Therapeutics pauses enrolment in phase 2 lymphoma study following patient deaths
Zynlonta was being evaluated along with rituximab in unfit or frail patients with DLBCL
FDA sets January decision date for Xalkori in ALK-positive lymphoma
FDA submission is based on results from ADVL0912 and A8081013 studies
NICE recommends Roche’s Polivy for B-cell lymphoma
Cost-effectiveness agency approves drug following initial rejection earlier this year
EU grants conditional approval to Roche’s lymphoma drug Polivy
Drug demonstrated a 40% complete response rate in trial
Incyte signs lymphoma deal worth up to $1.1bn with MorphoSys
Will pay $750m upfront for co-commercialisation rights
AstraZeneca wins FDA approval for Calquence in chronic lymphoma
Takes the fight to AbbVie and J&J's lymphoma rival Imbruvica
BeiGene gets speedy US review for lymphoma drug zanubrutinib
First US filing is major milestone for Chinese firm
Regeneron’s bispecific for lymphoma works in CAR-T failures
Regeneron has reported positive results with its REGN1979 drug in patients with non-Hodgkin’s lymphoma, including the evidence it can work in patients who have previously tried CAR-T therapies.The new data...